BSX

AI Memo

Boston Scientific

As of 2026-10-02/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-02 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

October 28 outlook reset after cyber disruption • 2026-10-28

Base target: $45 / p=45% prob

Biggest risk

The company reduced its full-year organic-growth outlook from 6.5%–8.0% in April to 5%–6% in July, then warned in September that the cyber incident likely prevents it from meeting the July sales and adjusted-EPS ranges. Citi subsequently downgraded BSX to Neutral and lowered its target to $50 from $57, citing uncertain recovery and competitive concerns. Q1 release [#SEC-8K-2026-07-29] [#SEC-8K-2026-09-08] The Fly

Invalidation

Break below $32 or thesis failure.

What would change my mind?

Q2 sales rose 7.5% and adjusted EPS of $0.86 exceeded the company's $0.82–$0.84 guidance. Cardiovascular sales grew 8.3% reported, and clinical progress supports a longer-term innovation case. If disrupted orders convert and October guidance clarifies a temporary rather than persistent setback, sentiment could recover. [#SEC-8K-2026-07-29] Earnings exhibit

Research note

Recommendation

—

Confidence

medium

As of

2026-10-02

Base target

$45

p=45%

Bull target

$56

p=25%

Bear target

$32

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Operational recovery and backlog conversion
FARAFLEX pivotal-trial progress
Q2 sales rose 7.5% and adjusted EPS of $0.86 exceeded the company's $0.82–$0.84 guidance.

BearKey bullets

Competitive pressure in U.S.
pulsed-field ablation and left-atrial-appendage closure is part of Citi's downgrade thesis.
The Fly

WatchKey bullets

October 28 outlook reset after cyber disruption

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $45 (p=45%)

Target spread vs base: +24% / -29%

Scenario probabilities

Bull Target: $56 (p=25%)Base Target: $45 (p=45%)Bear Target: $32 (p=30%)

Commentary

News tone is negative following the guidance warning and Citi downgrade, despite the company's reported operational restoration and favorable forensic update. The packet's September 14 article said shares were down 6.4% since Q2 results, but no verified immediate post-cyber or post-October-release price reaction is available; the October 1 price anchor is $43.23. Social, options, short-interest and employee measures were not supplied, so their zero placeholders are unavailable data, not neutral readings. The deterministic prior is positive, but the subsequent primary-source cyber disclosure materially weakens near-term confidence.

As of 2026-10-02 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Operational recovery and backlog conversion
FARAFLEX pivotal-trial progress

Scenarios

Bull Target (Scenario probability)

$56 / p=25% prob

Base Target (Scenario probability)

$45 / p=45% prob

Bear Target (Scenario probability)

$32 / p=30% prob

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.55

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-28
October 28 outlook reset after cyber disruption
Boston Scientific said the August 25 incident disrupted manufacturing and order fulfillment, is likely to materially affect Q3 and full-year results, and makes its July sales-growth and adjusted-EPS guidance unlikely to be met. It plans to update its outlook on October 28. The size of the shortfall and recoverable backlog are the key unknowns. [#SEC-8K-2026-09-08] SEC filing
Prob 100.00% • Move -5.00% • Priced-in 65.00%
EVENT2027-01-01
MedSurg and Asia-Pacific leadership transition
Arthur Butcher is scheduled to retire as group president of MedSurg and Asia Pacific effective January 1, 2027. The filing does not identify a successor; transition execution merits monitoring rather than an assumed operating impact. [#8-K-2026-09-23] SEC filing
Prob 95.00% • Move -1.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Operational recovery and backlog conversion
2026-10-28
The company reported that manufacturing, order fulfillment and shipping were restored, while its September 22 update reported no evidence of ongoing threat activity after containment. Restored operations do not establish how much deferred revenue will be recovered; order conversion remains the near-term test. [#SEC-8K-2026-09-08] [#PR-2026-09-22] Company update
Prob 60% • Move 6% • Priced-in 35%

Long-term Catalysts

Months to a year

FARAFLEX pivotal-trial progress
2027-12-31
Boston Scientific reported starting enrollment in the pivotal FARADIGM trial for its investigational FARAFLEX mapping and pulsed-field-ablation catheter. Enrollment and eventual clinical results could strengthen the atrial-fibrillation pipeline, but the company supplied no readout date in the reviewed release. [#SEC-8K-2026-07-29] Earnings exhibit
Prob 45% • Move 8% • Priced-in 30%

Risks

Competitive pressure in U.S. pulsed-field ablation and left-atrial-appendage closure is part of Citi's downgrade thesis. The Fly
Cyber-related revenue loss, backlog conversion and remediation costs remain unquantified; the company expects a material Q3 and full-year operating impact. [#SEC-8K-2026-09-08]
FARAFLEX remains investigational, and pivotal-trial timing and outcome are uncertain. [#SEC-8K-2026-07-29]
July sales-growth and adjusted-EPS guidance is unlikely to be met; the October 28 reset may reveal a larger or longer disruption than expected. [#SEC-8K-2026-09-08]

Peers

Symbol	Summary
ABT	Diversified medical-device comparison with cardiovascular exposure, but its broader businesses limit multiple comparability.
BDX	Broad medical-technology and hospital-exposure reference, less direct for pulsed-field ablation.
EW	Direct cardiovascular-device comparison, particularly relevant to structural-heart competition; product mix is not identical.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-02

Loading AI feed…

Symbol

Summary

ABT

Diversified medical-device comparison with cardiovascular exposure, but its broader businesses limit multiple comparability.

BDX

Broad medical-technology and hospital-exposure reference, less direct for pulsed-field ablation.

Direct cardiovascular-device comparison, particularly relevant to structural-heart competition; product mix is not identical.